Subgroup survival analysis identified the prognostic influence of mRNA expression for <i>BRCA1</i> among patients with luminal-B-like BC and for <i>BRCA2</i> and <i>PALB2</i> in the subset of patients with luminal-A-like BC (<i>p</i> < 0.050).<h4>Conclusions</h4>According to our observations, <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> expression might become valuable biomarkers of disease progression. The gene discussed is BRCA1; the disease is breast cancer.